



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/14, 1/10	A1	(11) International Publication Number: WO 99/33860 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/SE98/02468 (22) International Filing Date: 30 December 1998 (30.12.98) (30) Priority Data: 09/001,940 31 December 1997 (31.12.97) US 9800879-0 17 March 1998 (17.03.98) SE (71) Applicant (for all designated States except US): AMERSHAM PHARMACIA BIOTECH AB [SE/SE]; S-751 84 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): PILOTTI, Åke [SE/SE]; Tenorvägen 19, SE-183 38 Täby (SE). REGBERG, Tor [SE/SE]; Valhallavägen 104, S-114 41 Stockholm (SE). ELLSTRÖM, Christel [SE/SE]; Johannesbäcksgatan 36 A, S-754 33 Uppsala (SE). LINDQVIST, Charlotta [SE/SE]; Gropgränd 4, S-753 10 Uppsala (SE). ECKERSTEN, Ann [SE/SE]; Tjädervägen 25 B, S-756 53 Uppsala (SE). FÄGERSTAM, Lars [SE/SE]; Vattholmavägen 71, S-754 40 Uppsala (SE). (74) Agents: ROLLINS, Anthony, John et al.; Amersham Pharmacia Biotech Ltd., Amersham Labs, White Lion Road, Amersham, Bucks HP7 9LL (GB).		(81) Designated States: AU, CA, JP; US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR BINDING ALBUMIN AND MEANS TO BE USED IN THE METHOD (57) Abstract <p>A method for binding albumin by contacting an aqueous liquid containing an albumin with an albumin-binding compound is selected from albumin-binding compounds containing the scaffold -CO-NH-C(=C-)-CO-, and conjugates that are capable of binding albumin and exhibiting the scaffold -CO-NH-C(=C-)-CO-. An albumin-compound that has been obtained by changing the structure of the albumin binder exhibiting the scaffold -CO-NH-C(=C-)-CO-.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR BINDING ALBUMIN AND MEANS TO BE USED IN THE
METHOD

5 BACKGROUND OF THE INVENTION

Field of the Invention:

This invention concerns the use of a compound that is able to bind to albumin.

10 Description of the Related Arts

Albumin-binding ligands attached to a solid phase have been used for the removal of albumin from liquid samples mainly for two purposes: a) purification of albumin and b) further processing of the liquid samples in the absence of
15 albumin. In order to obtain a sufficient quality of the final albumin preparation, the step involving binding to an albumin ligand has often been combined with other steps including ion exchange and binding based on hydrophobic interaction. Both batch-wise and chromatographic processes have been described.

20 Albumin-binding ligands in soluble form have been used for desorption of albumin adsorbed to a matrix via an albumin-binding ligand (e.g. regeneration of adsorbents). The soluble ligand then competes with the ligand covalently attached to the matrix for the same binding site on albumin.

25 Arrays of compounds and single compounds exhibiting scaffold I have been described in WO 9622529, WO 9400509 and WO 9401102. However, the possibility of finding efficient albumin-binding ligands among individual members of these previously described arrays has hitherto not been recognised.

30

SUMMARY OF THE INVENTION


There is a demand for improved albumin binders having affinities, selectivities and/or specificities better adapted to the above-mentioned processes. There is also a need to
35 minimize the number of steps involved in the purification and removal of albumin from liquid samples.

There is also a need for separating albumins of different species from each other, for instance purifying human serum albumin from bovine serum albumin in the context of serum
40 albumin produced by transgenic cows.

CONFIRMATION COPY

The present invention aims at providing solutions to these demands and needs.

A first aspect of the invention provides a method for binding albumin by contacting an aqueous liquid containing an albumin with an albumin binding compound which comprises the structure (scaffold)



The nature of the binding is unknown, but it is believed that ionic, hydrophobic, dipole-dipole interactions and other interactions of non-covalent nature may be involved including also hydrogen bonds and a good geometric fitness between the compound and the binding site on an albumin molecule. This type of ability to bind will be referred to as affinity.

As described below the scaffold may be part of a conjugate or a free compound. The use may be expressed as a method for binding albumin to an albumin-binding compound wherein the compound is selected from albumin-binding compounds containing the scaffold I.

A second aspect of the invention is novel conjugates that exhibit the scaffold I activity where the substituents at the free valences in formula I are combined in a novel manner so as to optimize binding via affinity to an albumin.

By the term albumin is typically contemplated serum albumins from mammals and proteins having the analogous function in other vertebrates. The term albumin also encompasses albumin variants, such as genetically engineered forms, mutated forms, and fragments etc. having one or more binding sites that are analogous to a binding site unique for one or more vertebrate albumins as defined above. By analogous binding sites in the context of the invention are contemplated structures that are able to compete with each other for binding to one and the same ligand structure. In addition to serum albumin, albumins also encompasses lactalbumin, ovalbumin etc.


A low molecular weight (Mw) compound binding to one or more single binding sites on an albumin molecule through affinity will further on be called an albumin-binding ligand,

or simply ligand. An albumin-binding ligand covalently attached to a carrier molecule gives an albumin-binding ligand-carrier conjugate, or simply a ligand-carrier conjugate or conjugate. The carrier molecule may also be called conjugated partner. Conjugates may contain one or more ligand structures binding to albumin. For a specific conjugate the Mw of the carrier is as a rule larger than the Mw of the scaffold I, i.e. larger than 96 dalton.

The term "albumin binders" is used generically to encompass albumin-binding ligands, albumin-binding ligand-carrier conjugates and other compounds exerting affinity to albumin.

DETAILED DESCRIPTION OF THE INVENTION

We have thus found that improved albumin binders may be found among compounds of formula II:



L I G A N D C A R R I E R

C O N J U G A T E

The configuration around $-C=C-$ may be either Z or E, most likely with preference for the Z-isomer. The same applies also to Formula I. m is zero or 1. ----- represents that the conjugated partner is replacing a hydrogen in A, B, or $-L-G$. For $m = 0$, the compound of formula II reduces to a ligand and for $m = 1$ the compound is a conjugate. Determination of ability to bind albumin for a compound of formula II can be done as described below, but also prior art methods may be used.

The first aspect of the invention is a method for binding albumin by contacting a liquid medium containing albumin with an albumin binder under conditions permitting binding between albumin and the binder, wherein the binder is selected from among albumin binders comprising the scaffold $-CO-NH-C(=CH)-CO-$, and particularly those fulfilling formula II.

This aspect of the invention may be used for the removal or purification of albumin from a liquid sample. A liquid sample containing albumin is contacted with a conjugate according to formula II in which m is equal to 1 and the

conjugated partner is a carrier (matrix) that is soluble, insoluble or insolubilizable in aqueous liquid media.

In the case of purification of albumin, the matrix with bound albumin is separated from the liquid in a subsequent
5 step and the bound albumin released, collected and further processed using methods that are known in the art. For insoluble carriers and insolubilizable carriers that have been made insoluble, the binding step is called adsorption and the release step desorption.

10 The release of albumin from the carrier may be performed according to general principles known in the art, e.g. with agents binding to the same site on albumin as the ligand or with an agent changing the site so as to render binding difficult or impossible. Soluble albumin-binding compounds of
15 formula II, in particular where $m = 0$, may act as powerful releasing agents. The conditions (pH, ionic strength, temperature, etc.) for adsorbing/desorbing should be non-denaturing for albumin with respect to irreversible denaturation in particular. Soluble carriers may be
20 insolubilized after the binding step in order to facilitate physical separation of the complex between albumin and the ligand-carrier conjugate from the medium. Insolubilization steps typically take place before any release step.

A subaspect of the present invention is a method of
25 obtaining samples that are free of one or more of the albumins mentioned above, for instance for the purification of compounds other than the typical albumins as defined above. Release and washing steps may be included as in conventional purification of albumins in order to be able to reuse the
30 ligand-carrier material.

Removal of albumin according to the first aspect of the invention may be part of a chromatographic process utilizing as the conjugated partner an insoluble carrier in the form of a monolith or a population of particles/beads onto which
35 surfaces an inventive albumin binder has been immobilized. Particles/beads may be in the form of a packed or fluidised bed. Fluidised beds may be stably expanded allowing chromatographic processes to take place. Particulate carriers


may alternatively be used in batch-wise processes involving e.g. stirred suspensions.

The Ligand

5 Groups A and B

At two of the free valences in the scaffold (-CO-NH-C(=CH-)-CO- there may typically be a group containing a 5- or 6-membered aromatic ring providing two or three double bonds conjugated with the carbonyl group, with preference for the
10 left terminal carbonyl group, or with the carbon-carbon-double bond, respectively, of the scaffold (-CO-NH-C(=CH-)-CO-. The aromatic rings may typically comprise one, two or three heteroatoms providing at least one free electron pair and are selected from among oxygen, nitrogen or sulphur. The aromatic
15 rings may be fused to other aromatic or non-aromatic rings each of which may have heteroatoms as discussed above. In formula II the two groups containing the aromatic rings are represented by parts A and B. These parts are often interchangeable.

20 The 5- or 6-membered aromatic ring may be represented by the formula:



wherein ---- represents that R₁ and R₂ are substituting R₃, R₄ or a hydrogen in D.

The link from the aromatic ring to the scaffold I is
30 through replacement of a hydrogen in D or of one of R₁ and R₂, or one of R₃ and R₄. A link to the scaffold I through replacement of one of R₃ and R₄ is only possible provided that R₃ and R₄ do not define a bivalent structure that is part of a ring fused to the aromatic ring of formula III.

35 D in formula III is typically selected from among
-NH-CH=CH-, -CH=N-CH-, -NH-CH=N-, -NH-N=CH-, -N=N-NH-,
-S-CH=CH-, -O-CH=CH-, -O-CH=N-, -S-CH=N-, -CH=CH-CH=CH-,
-CH=CH-CH=N-, -CH=CH-N=CH-, -CH=CH-N=N-, -CH=NH-CH=N-,
-N=CH-CH=N-, -N=CH-N=N-, and -N=CH-N=N-. These structural units

may be inserted in either direction in formula III. Typically, the aromatic ring systems defined by formula III include phenyls, 1- and 2-naphthyls, 1- and 2-thienyls, 2-, 3- and 4-pyridyls, 2-, 3- and 4-quinolyls, 1-, 3- and 4-isoquinolyls, 2- and 3-indolyls, 2- and 3-furanyls, 1-, 2- and 3-pyrrolyls etc.

R₁ and R₂ may be selected from:

- a. hydrogen (no replacement), alkyl, aryl, alkoxy, aryloxy and their thio analogues, typically a C₁₋₁₀ alkyl or C₅₋₁₅ aryl groups optionally substituted with one or more halo groups, e.g. CF₃-, CH₃-, phenyl etc;
- b. halo, such as fluoro or chloro or bromo;
- c. nitro;
- d. cyano, carboxamido (-CONH₂) and carboxy (-COOH). Groups, such as N-substituted carboxamido (-CONH₂) with one or two amino hydrogens replaced with hydrocarbyl and hydrocarbyl esters and salts of carboxy, are included in carboxamido and carboxy, respectively. Typical hydrocarbyls are C₁₋₁₀ alkyl, such as arylalkyl or unsubstituted alkyl, or alkylaryl or unsubstituted aryl, for instance containing 5-15 carbons. Aryl groups may include phenyl, 1- and 2-naphthyls, 1-, 2- or 3-pyridyls etc.
- e. amino, such as primary, secondary and tertiary amino and corresponding ammonium groups and acylated and alkylated forms thereof including quaternary ammonium. Typical alkylated and acylated forms are those which are substituted with 1, 2 or 3 lower alkyls (C₁₋₁₂) or lower acyls (C₁₋₁₃), typically methyl or acetyl, respectively.

R₃ and R₄ may be hydrogen or together form a bivalent structure selected from among the D structures given above and in addition among -CH₂-S-CH₂-, -CH₂-O-CH₂-, -S-CH₂-CH₂-, -O-CH₂-CH₂-, -O-CH=CH-CH₂-, -CH₂-O-CH=CH-, -S-CH=CH-CH₂-, -CH₂-S-CH=CH-, -S-CH=CH-NH-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-CH₂-, -CH₂-CH=CH-, -CH₂-CH=CH-CH₂-, -CH₂-CH₂-CH=CH-. One can envisage that the albumin-binding activity also possibly may be at hand for other R₃ and R₄ than those specified here, for instance groups specified in a-e above.

Normal valence rules apply.

Group L-G

L is a linker attaching G to the scaffold -CO-NH-C(=CH-)-
5 CO- at the remaining free valence, in the preferred variant at the right carbonyl group as shown in formula II.

L is an organic structure and may be $-(CH_2)_n(X)_{m'}(CH_2)_{n'}$ - where the left and right free valences bind to the right carbonyl group of the scaffold and to the
10 group G, respectively. X may be oxygen, sulphur or NH with the hydrogen preferably being replaced with a methyl group or a C₂₋₁₀ alkyl. n and n' are integers 0-3 and m' is an integer 0 or 1 with the proviso that $n+n'+m'$ is 1, 2 or 3. One or more
15 of the hydrogen atoms in a CH₂-group of the linker may be replaced with a C₁₋₁₀ alkyl group, or a hydroxy, a carboxy or an amino group or any other group containing a functional group enabling further derivatization and linking to a carrier.

The best affinities for albumin have so far been
20 achieved for albumin binders in which X is NH with the hydrogen being replaced as suggested in the preceding paragraph and/or one or more of the CH₂-groups being substituted with a methyl and/or some other group as suggested in the preceding paragraph.

25 A preferred linker chain of the invention has substituents on the linker L so that rotation around bonds in the linker chain is hindered. Other means for hindering rotation in this part of the molecule may have similar effects on the affinity for albumin, for instance divalent groups
30 bridging a position in L-G with a position in A or B or in the scaffold.

G is typically a hydrophobic group, such as a straight, branched or cyclic hydrocarbyl which possibly is substituted with, for instance, halo or hydroxy groups, etc. Typically G
35 may be an aromatic group, such as phenyl, that may be substituted with a hydroxy and/or C₁₋₁₀ alkyl (e.g. methyl) in the ortho, meta or para position relative to the ring position binding to L.

The Conjugated Partner

In the conjugates of the present invention m is 1. The conjugated partner is linked to an albumin-binding ligand as defined in formula II via a bridge. The bridge may derive
5 wholly or partly from the ligand or from the conjugated partner. For the sake of simplicity the bridge will be discussed as an inherent part of the conjugated partner, unless otherwise specified.

The conjugated partner itself may comprise additional
10 albumin-binding ligands of the same or different structure as the ligand shown in formula II.

The conjugated partner may be attached to the ligand at a position in group A, B or L-G. It is preferred to have the conjugated partner attached

15 (a) at a functional group in the linker L as suggested above,
or

(b) at the aromatic ring structures in either part A or part B so that the bridge attaching the conjugated partner to the ligand structure will contain a sp^3 -hybridised carbon within
20 two atoms distance from the aromatic ring. The bridge may thus have: $-CH_2-CH_2-$, $-CH_2NH-$, $-NHCH_2-$, $-CH_2S-$, $-SCH_2-$, $-CH_2O-$, or $-OCH_2-$ next to the aromatic ring of part A or B.

The term "conjugate" in organic chemistry and biochemistry is well known and encompasses two or more
25 compounds which are linked together covalently so that properties from each compound are retained in the conjugate. In the context of the present invention, the term conjugate means that an albumin-binding ligand as defined in formula II ($m = 0$) is covalently linked (conjugated) to a compound
30 (conjugated partner) that has a property that is retained in the conjugate. Typically the conjugated partner may render the conjugate soluble, insoluble or insolubilizable in the media concerned, analytically detectable, reactive against a specified target such as a biospecific counterpart etc.

35 The conjugated partner (carrier) may be insoluble, insolubilizable or soluble in the liquid media concerned. Typical media are aqueous, including water possibly containing water-miscible organic liquids, and other liquid media in which binding to albumin may take place. Typical carriers are

based on organic or inorganic polymers which may be of synthetic or biological origin (biopolymers).

Insoluble carriers may be of the same kind as the carriers used as support in chromatography .

5 Suitable insoluble carriers may be of various physical forms such as monoliths, particles, tube walls etc. The carriers may be porous or non-porous.

The carrier may contain density controlling filler material (particles) embedded in a polymer.

10 Well known hydrophilic organic insoluble carriers are polymers which have on their liquid contact surface a plurality of hydrophilic groups, for instance hydroxy and/or amino and/or carboxy. Typical hydrophilic carriers are polyhydroxy polymers and polyamides, such as water-insoluble
15 forms of polyvinyl alcohol, poly(hydroxyalkyl methacrylates) and corresponding acrylates, polyacryl- and polymethacrylamides (for instance trisacrylamides and trismethacrylamides (tris = $(\text{HOCH}_2\text{CH}_2)_3\text{CNH}_2$ or $(\text{HOCH}_2)_3\text{CNH}_2$), polysaccharides, such as agarose, dextran, starch, pullulan,
20 and cellulose, which possibly have been cross-linked in order to render them better adapted for use as adsorption/chromatography matrices. To this group of carrier belongs also hydrophobic carriers that have been hydrophilized (e.g. coated with a hydrophilic compound) on outer and inner
25 (pore) surfaces.

Typical hydrophobic insoluble carriers are based on styrene-divinyl-benzene polymers, poly(alkyl methacrylates), polymers of perfluoro hydrocarbons (PFC) etc.

Inorganic variants of carriers may be based on materials
30 such as glass, zeolites, silica, composites, zirconium oxide, etc.


Typical examples of carriers that are soluble in aqueous media as defined above are water soluble polymers, such as dextran.

35 The conjugated partner may contain an analytically detectable label, such as an enzymatically active moiety, a fluorophor/fluorogen and a chromophor/chromogen etc. a moiety giving the conjugate a predetermined reactivity, such as biotin, or a chemically reactive group. Analytically

detectable conjugates may be useful in an assay such as immunoassay methods. Conjugates with a predetermined reactivity, such as biotin or a chemically reactive group will allow introduction of albumin-binding structures containing the scaffold I onto various types of other carriers, for instance for use in the above-mentioned methods for removal of albumin. These types of conjugated partners normally result in soluble conjugates.

Compounds of formula II may or may not bind to albumin. However, it is a routine matter to check for the albumin-binding capability of a certain compound. For instance, for quite a long time, there has been available a large number of well-characterized adsorbents with various ligand structures that provide affinity to albumin. In order to screen a large number of compounds and to optimize a certain general structure, albumin-binding experiments as outlined in the examples below are particularly useful. This screening method has enabled quick screening and optimization of compounds containing the inventive albumin-binding scaffold. A large number of albumin affinity compounds have been found. In principle any known method for checking affinity between two compounds may be modified and applied to screen for albumin-binding ligands. See for instance WO-A-9622530.

The conjugate of the second aspect of the invention has the formula (II):



wherein A, B, and L-G, and ---- are as defined above. The conjugated partner is a polymeric carrier. The conjugated partner is linked to the ligand either at the A- or B-part or at L. The preferred variants are those that are preferred for use in the first aspect of the invention.

For each albumin-binders having the scaffold in formula I, in particularly complying with formula II, one can look for further optimization of the binding activity by changing the various parts of the molecule. It can be envisaged that new albumin-binders found in this way must not necessarily comply

with formulae I or II. Accordingly, a third aspect of the invention are new albumin binders having been obtained by changing one or more structural elements of the structure of an albumin binder complying with formula I, in particularly
5 with formula II. This can be accomplished, for instance, by creating and screening chemical libraries in which the members differ around one structural elements of an albumin binder complying with formula I, in particular formula II. Structural elements to be changed may be the scaffold I, or part A, part
10 B or L-G of the presently claimed albumin binders. Typically at least one of these elements is retained in an albumin binder according to this aspect of the invention. By a chemical library is contemplated a collection (an array) of two, three or more structurally different compounds.

15

Synthesis Of Compounds of Formula II.

Compounds of formula II ($m=0$) may be synthesized starting from the appropriate oxazolone (unsubstituted at position 4) which is condensed with an aromatic aldehyde to substitute -
20 ~~CH₂- grouping in ring position 4 with a -C(=CH-Ar)- grouping~~ where Ar is an aromatic group of the aromatic aldehyde. Subsequently the oxazolone ring is opened with an amine or an alcohol comprising structure G. The various steps utilized are described in WO-A-9400509, WO-A-9401102, WO-A-9518186, WO
25 9518627, WO 9518972, WO-A-9517903 and WO 9622529, which are incorporated by reference in their entirety.

See also in the Examples - Synthesis, which describes further the synthesis of compounds of formula (II).

30

EXAMPLES

Screening Method

In order to screen for albumin-binding ligands, a
35 methodology using chromatography for indirect determination of ligand binding under non-equilibrium conditions is developed. Since non-equilibrium conditions are used, the kinetic rate constants of the interaction will have a pronounced effect on the binding 'signal' obtained. This is especially true for the

dissociation rate constant which, if it differs for different ligand species with the same affinity for the target, will give different binding 'signal' amplitudes. A similar approach was used by Zuckermann et al (Proc. Natl. Acad. Sci. USA 89 (1992) 4505-4509) which is incorporated by reference herein.

The procedure comprises the steps:

1. Incubate target with ligand.
2. Separate target from free ligand.
- 10 3. Analyse target fraction for presence of ligand.

Standard Assay

The ligand to be assayed was dissolved in PBS and mixed with HSA (100 mM HSA in PBS). The volume of the solution was selected so that the ratio between the ligand and HSA was 5:1 with final concentrations were for ligand 50 μ M in 10 μ M HSA (human serum albumin). The free ligand not bound to HSA was then removed by rapid passage through a HITRAP desalting column (SEPHADEX G25; Pharmacia Biotech AB, Uppsala, Sweden). The void fraction from the desalting column containing HSA and possible ligand complexed to HSA were collected and analysed by reverse phase chromatography (RPC) on HISEP 4.6/50 (SUPELCO, U.S.A.).

The result from the RPC step may be influenced by factors such as variation in ligand concentrations in the original ligand sample and differences in extinction coefficient for different ligands.

Instrumentation

30 Mixing step: GILSON 215 LIQUID HANDLER with a dilutor equipped with RACK 205 for deep well microtiter plates. RACK 202 for ELLERMAN tubes (KEBO, Sweden) equipped with a 1 ml dilutor syringe and a 1.5 ml transfer tubing.

Separation step: GILSON 215 LIQUID HANDLER with dilutor 35 equipped with a RACK 202 for ELLERMAN tubes (KEBO, Sweden), a 1 ml dilutor syringe and a 1.5 ml transfer tubing, and a

13

RHEODYNE fill port. FPLC System equipped with a HITRAP desalting column (SEPHADEX G25) (PHARMACIA BIOTECH AB, Uppsala). Sample dilution buffer and buffer A in FPLC: PBS (0.05 M Phosphate, 0.15 M NaCl, pH 7.0). Instant buffer for
5 gel filtration (MIKROKEMI AB, Uppsala, Sweden). Buffer B in FPLC: Buffer A + 20 % (volume) acetonitrile. Buffer A was used for the gel filtration step and buffer B was used to regenerate the HITRAP column.

Analysis step: SMART System with m-Peak Monitor. GILSON
10 234 AUTOINJECTOR (the synchronization contact input was connected to the auxiliary output of the SMART). HISEP 4.6 x 50 mm column (SUPELCO, U.S.A). Eluent A: 180 mM ammonium acetate/acetonitrile (19:1 vol/vol). Eluent B: 180 mM ammonium acetate/acetonitrile (1:9 vol/vol)


15

Libraries and Screening Thereof.

Starting library: Construction and result of screening.


A screening library (Screening Library 1) was set up in
order to screen for ligands that have affinity for IgG. No
20 efficient IgG binding ligands were found. Since the library was at hand it was also checked for albumin binders.

Screening Library 1 was constructed from four different oxazolones:




The oxazolones were condensed with 10 different heterocyclic aldehydes:


14



The obtained substituted oxazolones were subsequently opened 5 with 40 different amines (Table 4):



15




The products in the library array were not further purified.

5 Final yields were typically around 80%. The crude products (ligand samples) thus sometimes consisted of a mixture of final and/or intermediate products and/or starting materials.

When the oxazolones were reacted with aldehydes, isomers differing in double bond configuration may be formed. The Z/E-
10 ratio was typically 9:1, the stable Z isomer was the dominant one. This was confirmed by HPLC and ¹H NMR. After the opening of the oxazolone with an amine the Z/E-ratio was still 9:1 (without working up). This ratio could be shifted, e.g. by the
strong acidic/reductive conditions that was used to transform
15 a nitro group in the A part into an amino group by reduction with tin chloride.

Screening the Screening Library 1 with human serum albumin (HSA) as the target substance resulted in hits for about 10% of the compounds tested. The affinity varied from
20 weak to the extremely strong affinity found for Reference Compound 1 shown below, which is considered part of the present invention.



Reference Compound 1 is compound 23 in table 4. The library members that were positive for binding to HSA were also checked for binding to human IgG, lysozyme and human insulin.

5 Directed libraries and sublibraries were then constructed in order to map the Reference Compound 1-motif. Compounds containing handles and attachment points for carriers were synthesized based on similar conditions to those used for the synthesis of the original library.
10 Examples - Synthesis.

Experiments in Connection with Reference Compound 1.

The particular ligand sample containing Reference Compound 1 was obtained by reaction of 3-(2-thienyl)-oxazolone
15 with N-methyl-indole-3-aldehyde followed by subsequent ring-opening with ephedrine.

When the target substance (HSA = human serum albumin) and the ligand sample were mixed at equimolar concentration (10 mM) and applied directly to the RPC column, it was found that
20 this ligand sample contained at least four different compounds, one of which showed reactivity towards HSA. The ligand sample as such was therefore subjected to preparative RPC and the four compounds were isolated and examined by mass spectrometry. It was determined that the molecular weight of
25 the compound binding to HSA had a molecular weight of 473. In separate experiments two compounds with Mw 473, derivable from the reaction mixture and having NMR spectra suggesting they were the E and Z isomer, respectively were studied. Only Reference Compound 1 was active in binding to HSA. The results
30 suggested that Z isomer was active in binding to albumin. No conclusive results have so far been obtained for the E-isomer.

Kinetic Dissociation Experiments with Reference Compound 1

By letting mixtures of HSA and Compound 1 pass the HITRAP
35 column at different flow-rates (0.63 ml/min, 1.25 ml/min, 2.5 ml/min, 5 ml/min, 10 ml/min) the stability of the complex

could be assessed which corresponds to dissociation times of 172 to 10.8 seconds.

After integration of the HSA and ligand peaks in the chromatograms, differences in the sample concentrations were corrected for by normalization of the HSA peaks. The ligand peak area as a function of dissociation time could be determined as shown by Table 1 below. By non-linear curve fitting, the data were interpreted to represent parallel and independent dissociation of ligand from two different binding sites on the HSA molecule according to:

$$[TL]_t = [TL(1)]_0 * e^{-kdiss1*t} + [TL(2)]_0 * e^{-kdiss2*t}$$

where TL(1) and TL(2) denote the two types of complexes with the apparent dissociation rate constants $kdiss1$ and $kdiss2$, respectively, and t denotes the time from start of dissociation.

Table 1.

t_0 (s)	Area1 (A _{Umin})	$kdiss1$ (s ⁻¹)	Area2 (A _{Umin})	$kdiss2$ (s ⁻¹)
10.8	8.09	2.19e-3	5.91	5.15e-2

A_{Umin} stands for the integrated peak area in those chromatograms that were recorded in the kinetic study (adsorbance units on the y-axis and minutes on the x-axis).

Area1 and Area2 reflect the amount of ligand bound to the respective sites after 10.8 seconds (t_0) of dissociation. By extrapolation to zero time the complex stoichiometry (at saturation) in the incubation mixture can be estimated. Standard curves for HSA and ligand were constructed and used to calculate the molar ratio which was found to be close to 2:1 (ligands/HSA).

Reference Library

AN1001 described in WO-A-9622529 was used as a reference library. It is an array based on oxazolones and contains 8000 compounds. It is a general library having members represented by formula II with known pharmacophore structures, usually

aromatics, as groups A, B and L-G. Due to difficulties in solubilizing many of the members, it was never completely screened for albumin binders. The library was only used as a source for selecting interesting structures to be tested for binding to serum albumin.

RESULTS OF THE SCREENINGS

Variations in the A-group

The main objective of the synthetic design-work around the aromatic ring in the starting oxazolone (A-group) was to introduce a handle for attachment of the albumin ligand to a matrix. For the synthesis of different A-group analogues see Examples - Synthesis. A phenyl ring substituted with one or more of carboxylic acid function, amino, nitro, aminomethyl, chloromethyl, cyano and vinyl groups, for example, groups that either could be used directly for coupling or be converted to a coupling group were considered.

Vinylphenyl and chloromethylbenzyl oxazolones could not be used due to polymerization reactions. The cyanophenyl oxazolone derivative could be brought through the synthesis successfully, but the cyano group then could not be transformed into a carboxylic acid for later attachment to a matrix. These unsuccessful synthetic routes do not mean that the planned final product will bind to albumin.

The starting materials (A-, B- and L- G-group) for compounds that were synthesized with the goal to introduce a handle in the A-group are given in Table 2 which include compounds that have been tested for binding to serum albumin.

Table 2. Oxazolones with various handles in the A-part and different fused two-ring aromatic groups in the B-part.

No	A-part	B-part	L-G from	Act.
1	4-nitro-phenyl	N-methyl-indoly-3-yl	1R, 2S-(-) - ephedrine	+
2	4-nitro-phenyl	Naphth-1-yl	1R, 2S-(-) -	+

			ephedrine	
3	4-nitro-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	I
4	4-nitro-phenyl	Quinolin-4-yl	1R,2S-(-)-ephedrine	-
5	4-amino-phenyl	N-methyl-indoly-3-yl	1R,2S-(-)-ephedrine	(+)
6	4-amino-phenyl	N-methyl-indoly-3-yl	1R,2S-(-)-ephedrine	(+)
7	4-amino-phenyl	Quinolin-4-yl	1R,2S-(-)-ephedrine	(+)
8	4-amino-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	+
9	4-amino-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	(+)
10	4-cyano-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	(+)
11	4-(NH ₂ CO-)-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	(+)
12	4-(benzyl-CONHCH ₂)-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	I
13	4-(aminomethyl)-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	-
14	4-(CH ₃ CO-NHCH ₂)-phenyl	Naphth-1-yl	1R,2S-(-)-ephedrine	+

Compounds 2 and 3 are isomers.

"+" represents strong binding, "(+)" weak binding and
 "- " no binding.

5 "X" represents the link to the scaffold. "Act" is activity
 and

"I" is insoluble.

For details on synthesis see Examples - Synthesis. The results
 of the testing for affinity to albumin are apparent from Table
 10 2. All of the amino-substituted phenyloxazolones were more or

less active, while the nitro-, cyano-, amide-substituted compounds differed in activity.

Coupling of active compounds at functional groups directly attached to the phenyl ring (A-group) to insoluble carriers gave conjugates that were more or less inactive in binding to albumin. Conjugates that were active in binding to albumin were obtained in the case of a methylene group was inserted between the functional group used for attachment of the conjugated partner and the aromatic ring of the A-group. The rationale for this may be that a methylene group and other chains comprising sp^3 -hybridized atoms at this position make the linkage between the ligand structure and the conjugated partner more flexible and facilitates rotation.

15 Variations in the B-part

The screening of Library 1 and selection of compounds from the reference library gave insight to the requirements for this part. It appeared favourable with structures such as fluoro containing single aromatic rings, fused two-ring systems and also pyridine rings.

The syntheses to introduce a handle on the B-part was restricted to indoles. N-allyl-indole-3-aldehyde and N-chlorobutylindole-3-aldehyde were synthesized. Some of the starting indoles also exhibited methyl substituents at various positions. Tested compounds are given in Table 3.

Table 3. Variations in the B-part.

No	A-part	B-part	L-G from	Act.
15	thiophen-2-yl	N-allyl-indol-3-yl	1R,2S-(-)-ephedrine	+
16	thiophen-2-yl	N-(4-chlorobutyl)-indol-3-yl	1R,2S-(-)-ephedrine	(+) dil 1+3


I, Act, X, (+), + and - have the same meaning as in Table 2.

The rules for the B-part retaining affinity to albumin when linking an active albumin-binding ligand to a conjugated partner should be similar to the rules for the A-part.

5 Variations in the L-G-part

From the screening of Library 1 against serum albumin and some other proteins it was concluded that the L-G part, in particular the ephedrine part, was important for high activity and selectivity for serum albumin. Low binding activity could be obtained for other groups, primarily those originating from oxazolone ring opening with hydrophobic amines (R-NH₂ where R may be an hydrocarbyl group, such as aryl or alkyl group). It is likely that this effect is retained even if the hydrocarbyl group has one or more smaller hydrophilic groups that do not completely overcome the hydrophobicity. Only ligands with L-G-parts deriving from ephedrine were therefore selected, when ligands from the reference library were selected for testing.

Most of the synthetic work was focused on the L-G-part of the molecule. Various L-G-part analogues of Reference Compound 1 were prepared from ephedrine and norephedrine (which is missing the N-methyl group) and some other ephedrine analogues:



The results for ephedrine analogues are given in Tables 4 and 5.

Table 4. Result in activity for the products from reaction of 1-methylindole-3-thienyloxazolone with different amines.

No	L-G from	Solvent	Triethyl amine	Temp	Act
17	1R,2S-(-)-1-phenyl-1-hydroxy-2-amino-propane	THF		55°C	-
18	L-1-phenyl-2-amino-3-hydroxy-propane	THF		55°C	(+)
19	D-1-phenyl-2-amino-3-hydroxy-propane	THF		55°C	(+)
20	1S,2R-(+)-ephedrine	THF		55°C	+
21	1S,2S-(+)-ephedrine	THF		55°C	+
22	1S,2R-(+)-1-phenyl-1-hydroxy-2-amino-propane	THF		55°C	+
23	1R,2S-(-)-ephedrine	THF		55°C	+
24	L-phenylalanine	ACN/H ₂ O (5:2)	2.4 eq	70°C	-
25	S,3R-3-phenyl-pyrrolidine-2-carboxylic acid	ACN/H ₂ O (5:2)	2.4 eq	70°C	-
26	N-methyl-L-phenylalanine	ACN/H ₂ O (5:2)	2.4 eq	70°C	+

27	N-methyl-D-phenylalanine	ACN/H ₂ O (5:2)	2.4 eq	70°C	+
----	--------------------------	-------------------------------	--------	------	---

I, Act, X, (+), + and - have the same meaning as in Table 2.

Table 5. Activity for compounds obtained by ring-opening where the opening of the oxazolones has been done with different amines.

No	A-part	B-part	L- G- from	Reaction conditions	Act.
28	thiophen-2-yl	naphth-1-yl	1S,2S-(+)-ephedrine	55°C THF	I
29	thiophen-2-yl	naphth-1-yl	1S,2R-(+)-norephedrine	55°C THF	(+) Dil 1+1
30	thiophen-2-yl	naphth-1-yl	1R,2S-(-)-ephedrine	55°C THF	I
31	thiophen-2-yl	naphth-1-yl	N-methyl-L-phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 70°C	-
32	thiophen-2-yl	naphth-1-yl	N-methyl-D-phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 70°C	(+)
33	phenyl	naphth-1-yl	1S,2S-(+)-ephedrine	55°C THF	I
34	phenyl	naphth-1-yl	1S,2R-(+)-norephedrine	55°C THF	-
35	phenyl	naphth-1-yl	1R,2S-(-)-ephedrine	55°C THF	(+) dil 1+1
36	phenyl	naphth-1-yl	N-methyl-L-phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 70°C	-
37	phenyl	naphth-1-	N-methyl-D-	ACN/ H ₂ O	(+)

		yl	phenylalanine	(3:1), 2.3 eq TEA, 70°C	
38	phenyl	N-methyl- indol-3-yl	1S,2S-(+)- ephedrine	55°C THF	I
39	phenyl	N-methyl- indol-3-yl	1S,2R-(+)- norephedrine	55°C THF	-
40	phenyl	N-methyl- indol-3-yl	1R,2S-(-)- ephedrine	55°C THF	+
41	phenyl	N-methyl- indol-3-yl	N-methyl-L- phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 70°C	(+)
42	phenyl	N-methyl- indol-3-yl	N-methyl-D- phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 70°C	(+)
43	thiophen- 2-yl	N-methyl- indol-3-yl	(±)-synephrine	THF/ACN (1:1), 70°C	-
44	thiophen- 2-yl	N-methyl- indol-3-yl	L- phenylalanine	ACN/ H ₂ O (7:1), 2.3 eq TEA, 70°C	-
45	thiophen- 2-yl	N-methyl- indol-3-yl	N-methyl-L- phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 55°C	(+)
46	thiophen- 2-yl	N-methyl- indol-3-yl	N-methyl-D- phenylalanine	ACN/ H ₂ O (3:1), 2.3 eq TEA, 55°C	(+)
47	thiophen- 2-yl	N-methyl- indol-3-yl	p-hydroxy- ephedrine hydrochloride	ACN/ H ₂ O (4:1), 1 eq TEA, 55°C	-

I, Act, X, (+), + and - have the same meaning as in Table 2.


The results presented in Table 4 illustrate that the albumin-binding activity may be enhanced if L contains a group that can stabilize the conformation by the introduction of a rotational barrier around the nitrogen and the C1 carbon in ephedrine (in this case a methyl that is γ to the phenyl ring). The finding that a functional group permitting coupling

to a conjugated partner could be introduced in the L- G-part was important (N-methyl-phenyl alanine).

The results presented in Table 5 illustrate that phenyl- and thienyl oxazolones and indolyl and naphthyl aldehydes can be used to introduce parts A and B, respectively, in the case where the L-G-part derives from ephedrine analogues. Solubility problems appeared when the groups in the A- and the B-part are too hydrophobic.

10 Binding Specificity

Reference Compound 1 and its N-methyl alanine D and L analogues A3 and B3, respectively:



15 were tested under ordinary screening conditions for binding to HSA, lysozyme, IgG and insulin in order to test the specificity for serum albumin. Except for HSA, none of the proteins bound to these ligands. Binding of serum albumin from other species was also
20 tested. The results in the latter case were non-conclusive leaving the question open if the novel albumin binders comprise ligands that will discriminate between, for instance, bovine and human serum albumins.

25

Reference library: Tested compounds that have affinity to serum albumin

L-G-part derived from ring opening with ephedrine. For the below groups A group B has been:

26

- A = phenyl: B = 3- trifluoromethyl
phenyl, 4-trifluoro-methyl phenyl, 1-naphthyl.
- A = 3-methoxy phenyl: 2,4-difluoro phenyl, 2-fluoro
phenyl, 3-fluoro phenyl, 4-trifluoromethyl phenyl,
5 2-methyl phenyl, 3-pyridyl, 2-pyridyl.
- A = 2-naphthyl: 2,4-difluoro phenyl, 3-fluoro phenyl,
4-fluoro phenyl, 2-methyl phenyl.
- A = 2-thienyl: 3-fluoro phenyl, 4-fluoro phenyl, 1-
naphthyl.
- 10 A = 4-trifluoromethyl phenyl: 2,4-difluoro phenyl, 3-
fluoro phenyl, 4-fluoro phenyl, 2-methyl phenyl,
3-chloro phenyl, 3-pyridyl, 4-pyridyl, 4-chloro
phenyl, 3-quinolyl.
- A = 2,4-dichloro phenyl: 2,4-difluoro phenyl, 2-fluoro
15 phenyl, 2-trifluoromethyl phenyl, 3-
trifluoromethyl phenyl, 2-methyl phenyl, 4-
methoxy-phenyl, 4-phenyl phenyl, 1-naphthyl, 3,5-
difluoro phenyl, 4-pyridyl, 3-quinolyl.
- A = 4-methyl phenyl: 2-fluoro phenyl, 2-methyl phenyl,
20 4-methoxy phenyl, 3,5-difluoro phenyl.
- A = 3-methyl phenyl: 3-fluoro phenyl, 4-fluoro phenyl,
2-trifluoromethyl phenyl, 1-naphthyl, 4-
trifluoromethoxy phenyl, 3-phenoxy phenyl.

25 Methods and Analyses

The characterization was performed on a JEOL ECLIPSE-
270MHz NMR. The samples were run in 5mm:s probes and the
substances were dissolved in CDCl₃ or DMSO-d₆. TMS was used as
an internal standard. TLC was run on MERCK KIESELGEL F₂₅₄ and
30 was eluted with ethylacetate and then developed under UV-light
(254 nm). HPLC was performed on a SMART System on a SUPELCO
HISEP column.

References

1. Y. S. Rao and R. Filler, Geometric Isomers of 2-
35 Aryl(Aralkyl)-4-arylidene(alkylidene)-5(4H)-oxazolones,

Synthesis 749-764, 1975, incorporated by reference herein in its entirety.

5 EXAMPLE - SYNTHESIS

In each of the examples 1-8 presented below, factors such as solvents, temperatures, order of additions, reaction times and working up protocols, etc. were selected so as to fit the reactants used. ¹H NMR, MS and HPLC results provide support that the desired compounds had been obtained. If needed also other criteria for checking the outcome of the individual reactions were employed.

Example 1. Compounds of formula II with A = thien-2-yl; B = 1-methyl-indol-3-yl, 1-allyl-2-methyl-indol-3-yl, naphth-1-yl or 1-(4-chlorobut-1-yl)-indol-3-yl

A. Synthesis of the starting oxazolone.

N-thiophene-2-carboxamide glycine: In a 1000ml 3-necked reaction flask 77.0g glycine was dissolved in 600ml water with a mechanical stirrer. NaOH (12.0g) was added to form sodium glycinate. The reaction mixture was then cooled to 5 °C. Thiophene carbonyl chloride was added dropwise and conc. NaOH-solution (50%) was periodically added to keep pH around 10 during 1.5h. The temperature rised to 12°C during the addition and the solution became homogeneous. After another hour conc. HCl (70ml) acidified the mixture to pH 2 and the stirring continued for two hours. The precipitated crystals were filtered off and washed with water. The product was confirmed with NMR after drying in a vacuum oven at 60°C. ¹H NMR shifts: δ = 4.05 (s, 2H), δ = 7.12 (dd, 1H), δ = 7.65 (dd, 1H), δ = 7.71 (dd, 1H). Yield: 90-100% (ca.130g).

2-(Thien-2-yl)-oxazolone: In a 2L 3-necked flask with mechanical stirrer 66.8g dicyclohexylcarbodiimide (DCC) was dissolved in 100ml anhydrous THF. Thiophene-2-carboxamiddeglycine dissolved in 600ml anhydrous THF was added dropwise during 30min. The reaction mixture was then

allowed to stir for 24 hours at room temperature. The mixture was cooled to 5°C and dicyclohexylurea was filtered off. After evaporation of THF the solid product was dissolved in hot dichloromethane and then cooled so that more dicyclohexylurea could be filtered off. The solution was evaporated and chromatographed on 400g silica through a 15cm wide column with dichloromethane. The first 3L was collected and evaporated to give 19g product. ^1H NMR shifts: $\delta = 7.14$ (dd, 1H), $\delta = 7.59$ (dd, 1H), $\delta = 7.7$ ppm (dd, 1H). Yield: 35% (19g).

B1. Introduction of 1-methyl-indol-3-yl as ring system B.

2-(thien-2-yl)-oxazolone 3.0g (18mmol) was mixed with 2.0g (12.6mmol) 1-methylindole-3-aldehyde in 12ml toluene in a screw-cap tube. Triethylamine (0.8ml) was added and the closed tube placed on a heating block at 70°C over night. The dark red-brown reaction mixture, with crystals in, diluted with 200ml toluene and acetone, then extracted with 3x100ml water. The toluene layer was dried with MgSO_4 , evaporated to 20ml and then crystals fell over night and these were dried in a vacuum-oven at 60°C. ^1H NMR showed that some starting material was still present. The product was recrystallized from toluene and ^1H NMR confirmed the product. ^1H NMR shifts: $\delta = 3.93$ (s, 3H), $\delta = 7.17$ (dd, 1H), $\delta = 7.3-7.4$ (m, 3H), $\delta = 7.60$ (dd, 1H), $\delta = 7.62$ (s, 1H), $\delta = 7.81$ (dd, 1H), $\delta = 7.95$ (d, 1H), $\delta = 8.42$ (s, 1H). Yield: 23% (0.89g).

B2. Introduction of naphth-1-yl as ring system B.

2-(thien-2-yl)-oxazolone 2.5g (15mmol) was mixed with 2.3g (15mmol) naphthalene-1-aldehyde in 12ml toluene in a screw-cap tube. Triethylamine (1.0ml) was added and the closed tube placed on a heating block at 70°C over night (17h). The precipitated crystals were dissolved in 100ml toluene and 50ml acetone and the mixture was heated until all was in solution. After crystals had fallen and been collected, a ^1H NMR spectrum was run which showed that some starting material was left. After recrystallization in toluene, ^1H

29

NMR confirmed the pure product. ^1H NMR shifts: δ = 7.21 (dd, 1H), δ = 7.40 -7.66 (m, 4H), δ = 7.69 (dd, 1H), δ = 7.90 (d, 1H), δ = 7.92 (dd, 1H), δ = 7.97 (d, 1H), δ = 8.08 (s, 1H), δ = 8.30 (d, 1H), δ = 8.97 (d, 1H). Yield: 18% (0.83g)

B3. Introduction of 1-allyl-2-methyl-indol-3-yl as ring system B.

1. Synthesis of N-allyl-2-methyl-indole-3-aldehyde.

2-Methyl-indole-3-aldehyde (3.18g, 20mmol) and KOH (1g) dissolved in 15ml DMSO was added dropwise to allylbromide (2.6ml, 30mmol) dissolved in 5ml DMSO at 60°C and stirring. A saturated aqueous solution of KOH was added during the reaction to keep the pH 10-11. Totally about 4ml KOH-solution was added. The reaction mixture was partitioned between toluene and water. The toluene-layer was carefully extracted with water several times. The organic phase was evaporated to an oil containing DMSO. It was extracted again between diethyl ether/toluene and water, and the organic phase evaporated to give an oil. When 5ml diethyl ether was added crystallization took place immediately. After the crystals were filtered and washed with diethyl ether/hexane they were recrystallized from 25ml diethyl ether. TLC in toluene/EtOAc (1:1) showed approximately 95% purity and ^1H NMR confirmed the product. ^1H NMR shifts: δ = 2.64 (s, 3H), δ = 4.71 (d, 1H), δ = 5.17 (d, 1H), δ = 5.85 (d, 1H), δ = 5.90 (m, 1H), δ = 7.25 (m, 3H), δ = 8.27 (d, 1H), δ = 10.18 (s, 1H=aldehyde). Yield: 58% 2.3g).

2. Introduction of 1-allyl-2-methyl-indol-3-yl as ring system B. 2-(thien-2-yl)oxazolone (400mg, 2.4mmol) and 1-allyl-2-methyl-indole-3-aldehyde (477mg, 2.4mmol) were dissolved in 2.5ml toluene in a screw-cap tube. Triethylamine (163 μ l, 2.4mmol) was added and the closed tube placed on a heating block at 70°C over night (17h). When the tube cooled; crystals were formed and these were collected and washed with cold toluene. The crystals were then recrystallized two times from toluene and after drying

in a vacuum oven at 60°C, ¹³⁰¹H NMR confirmed the product. ¹H NMR shifts: δ = 2.61 (s, 3H), δ = 4.75 (d, 2H), δ = 4.88 (dd, 1H), δ = 5.20 (dd, 1H), δ = 5.93 (m, 1H), δ = 7.25-7.36 (m, 3H), δ = 7.51 (s, 1H), δ = 7.57 (dd, 1H), δ = 7.79 (dd, 1H), δ = 9.18 (d, 1H). Yield: 13% (110mg).

B4. Introduction of 1-(4-chlorobut-1-yl)-indol-3-yl as ring structure B.

1. Synthesis of 1-(4-chlorobut-1-yl)-indole-3-aldehyde.

Indole-3-aldehyde (1.45g, 10mmol) was dissolved in 5.0ml dry DMSO, and KOH (0.5g) was added. 1-bromo-4-chlorobutane (2.57g, 15mmol), dissolved in 3ml DMSO, was added in 3 portions during 3h. The reaction was shaken at 60°C. At each addition of 1-bromo-4-chlorobutane, 0.5ml 45°C KOH was added (totally 1.5ml). After the reaction was completed the reaction mixture was extracted with H₂O/toluene several times. The organic phase was evaporated to yield an oil which was dissolved in diethyl ether (45ml) and kept at -20 °C for 3 days. The solid was filtered off and washed with ether and dried. Yield: 76% = 1.8g. TLC showed a very small spot of impurity (ca 10%), possibly the C-2 chlorobutane derivative. Due to this, the product was recrystallized from diethyl ether with a small volume of acetone (total volume ca 10ml). The products cocrystallized so a short silica column was run and the products eluted with toluene/EtOAc 2:1 to give pure compound. ¹H NMR shifts: δ = 1.80 (q, 2H), δ = 2.07 (q, 2H), δ = 3.53 (t, 2H), δ = 4.20 (t, 2H), δ = 7.25-7.35 (m, 3H), δ = 7.70 (s, 1H), δ = 8.30 (d, 1H), δ = 9.99 (s, 1H).

2. Introduction of ring structure B. 2-(thien-2-yl)-oxazolone (500mg, 3mmol) and N-(4-chlorobutane)indole-3-aldehyde (700mg, 3mmol) were dissolved in 3ml toluene in a screw-cap tube. Triethylamine (200μl, 3mmol) was added and the closed tube placed on a shaking heating block at 70°C over night (17h). The reaction mixture was dissolved in 10ml toluene and 5ml acetone and extracted with 3x10ml water. The toluene phase was dried with MgSO₄ and

evaporated. A short silica column was run and the products eluted with toluene/EtOAc 9:1 to give a pure compound. ^1H NMR shifts: $\delta = 1.86$ (q, 2H), $\delta = 2.13$ (q, 2H), $\delta = 3.57$ (t, 2H), $\delta = 4.29$ (t, 2H), $\delta = 7.13-7.22$ (m + dd, 1+1H), $\delta = 7.29-7.41$ (m, 3H), $\delta = 7.60$ (dd, 1H), $\delta = 7.61$ (s, 1H), $\delta = 7.82$ (dd, 1H), $\delta = 7.95$ (m, 1H), $\delta = 8.42$ (s, 1H). Yield: 24% (280mg).

C. Reaction of oxazolones with amines (introduction of ring structure C (i.e. -L-G)).

The oxazolone is mixed with the amine and the solvent in a screw-cap tube. The tube is placed on a heating block over night (18h) and then the solvent is evaporated with heat and/or nitrogen. The synthetic products were not purified further, but used as they were. The raw products were analyzed with HPLC, TLC and some of them with ^1H NMR and ESMS and found to agree with the expected compounds. The amines used are given above under the heading "Variations in the L-G-part". The solvent, temperature and addition of triethyl amine are provided in Tables 4-5.

Example 2. Compounds of formula II with A = Phenyl; B = 1-methyl-indol-3-yl or naphth-1-yl

A1. Introduction of 1-methyl-indol-3-yl as ring system B. 2-phenyloxazolone 5g (31mmol) was dissolved with 4.93g (31mmol) 1-methylindol-3-aldehyde in 30ml toluene in a screw-cap tube. Triethylamine (2.0ml) was added and the closed tube placed on a heating block at 70°C over night (17h). The precipitated crystals were dissolved in 200ml toluene and 100ml acetone and the mixture was heated until all was in solution. After crystals had fallen and been collected, a ^1H NMR spectrum was run which showed that some starting material was left. After recrystallization from toluene, ^1H NMR confirmed the pure product. ^1H NMR shifts: $\delta = 3.95$ (s, 3H), $\delta = 7.30-7.40$ (m, 3H), $\delta = 7.47-7.58$ (m, 3H), $\delta = 7.65$ (s, 1H), $\delta = 7.99$ (dd, 1H), $\delta = 8.15$ (dd, 2H), $\delta = 8.45$ (s, 1H). Yield: 37% (3.46g).

A2. Introduction of naphth-1-yl as ring structure B.

2-Phenyloxazolone 2.5g (16mmol) was dissolved together with 2.42g (16mmol) 1-naphthaldehyde in 15ml toluene in a screw-cap tube. Triethylamine (1.0ml) was added and the closed tube placed on a heating block at 70°C over night (17h). The solvent was evaporated with heat and nitrogen and the reaction mixture was dissolved in hot ethyl acetate and a few drops of methanol and then cooled. The crystals that grew from the solution were characterized to be the product by ¹H NMR. ¹H NMR shifts: δ = 7.50-7.68 (m, 6H), δ = 7.90 (d, 1H), δ = 7.97 (d, 1H), δ = 8.14 (s, 1H), δ = 8.21 (dd, 2H), δ = 8.31 (d, 1H), δ = 9.2 (d, 1H). Yield: 34% (1.64g).

B. Reaction of oxazolones with amines (introduction of ring structure G (i.e. -L-G)).

The oxazolone is mixed with the amine and the solvent in a screw-cap tube. The tube is placed on a heating block over night (18h) and then the solvent is evaporated with heat and/or nitrogen. The synthesized products were not purified further, but used as they were. The raw products were analyzed with HPLC, TLC and some of them with ¹H NMR and ESMS. The amines used are provided above, under the heading "Variations in the L-G-part". The solvent, temperature and addition of triethyl amine are given in Tables 4-5.

Example 3. Compounds of formula II with A = 4-nitro-phenyl; B = 1-methylindol-3-yl or quinol-4-yl; -L-G deriving from (-)-(1R, 2S)-ephedrin.

Solvents, temperature, order of addition, reaction times and working up protocol were selected so as to fit the reactants used. ¹H NMR, MS, HPLC results provided support that the desired compounds had been obtained.

A. 2-(4-nitro-phenyl)oxazolones. This compound was prepared by acetic anhydride cyclization of 4-nitrohippuric acid.

B1. Introduction of 1-methylindol-3-yl as ring system B and of structure -L-G by oxazolone ring opening with (-)-(1R, 2S)-

ephedrine. These two steps were carried out as described above for other oxazolones, aldehydes and amines, the aldehyde now being 1-methylindol-3-aldehyde.

B2. Introduction of naphth-1-yl as ring system B of structure -L-G by oxazolone ring opening with (-)-(1R, 2S)-ephedrine.

These two steps were carried out as described above for other oxazolones, aldehydes and amines, the aldehyde now being naphthalene-1-aldehyde.

B3. Introduction of quinol-4-yl as ring system B and of structure -L-G by oxazolone ring opening with (-)-(1R, 2S)-ephedrine. These two steps were carried out as described above for other oxazolones, aldehydes and amines, the aldehyde now being quinoline-4-aldehyde.

Example 4. Compounds of formula II with A = 4-aminophenyl and N-acetyl-4-aminophenyl; B = 1-methylindol-3-yl, naphth-1-yl or quinol-4-yl; and -L-G deriving from (-)-(1R, 2S)-ephedrine.

A1.1. SnCl₂ reduction of the ring-opened product of Example 3B1. A = 4-aminophenyl; B = 1-methylindol-3-yl. The

compound obtained in Example 3B1 was reduced with SnCl₂.

A1.2. SnCl₂ reduction of the ring-opened product of Example 3B2. A = 4-aminophenyl; B = naphth-1-yl. The compound obtained in Example 3B2 was reduced with SnCl₂.

A1.3. SnCl₂ reduction of the ring-opened product from Example 3B3 to its amino analogue. A = 4-aminophenyl; B = quinol-4-yl. The compound obtained in Example 3B3 was reduced with SnCl₂.

A2. Catalytic reduction of the ring-opened product of Example 3B1. A = 4-aminophenyl; B = 1-methylindol-3-yl. The compound obtained in Example 3B1 was reduced with H₂ on Pd/C. The product was identified to be the same as in Example 4A1.1.

B1. Acylation of an 4-amino phenyl group in part A. The product from Example 4A1.1 was acylated with acetic acid anhydride.

Example 5. Compounds of formula II with A = N-acetyl-4-aminophenyl; B = naphth-1-yl; and -L-G deriving from (-)-(1R,2S)-ephedrine.

- 5 A. Introduction of ring systems A and B. This was done by reacting 2-(N-aceto-4-aminophenyl) oxazolone with naphthalene-1-aldehyde.
- 10 B. Introduction of the structure -L-G by oxazolone ring opening with (-)-(1R,2S)-ephedrine. This was done in analogy with the above-given procedures and other combinations of oxazolones, aldehydes and amines.

Example 6. Compounds of formula II with A = 4-cyanophenyl; B = naphth-1-yl; and -L-G deriving from (-)-(1R, 2S)-ephedrine.

- 15 A. 2-(4-Cyanophenyl)oxazolone. This compound was obtained from reaction of 4-cyanobenzoyl chloride with glycine to give 4-cyanohippuric acid that subsequently was cyclized with Ac₂O.
- 20 B. Condensation of 2-(4-cyanophenyl)oxazolone and naphthalene-1-aldehyde. This reaction was carried out in analogy with the procedures given above for other oxazolones and aldehydes.
- 25 C. Opening of the oxazolone ring with (-)-(1R, 2S)-ephedrine. The oxazolone product from the preceding step was reacted with the amine as outlined above for other oxazolones.

Example 7. Compounds of formula II with A = 4-H₂NCO-phenyl; B = naphth-1-yl; and -L-G deriving from (-)-(1R, 2S)-ephedrine. This product was obtained by hydrolysing the product of Example 6C under oxidative conditions.

30 Example 8. Compounds of formula II with A = 4-aminomethyl-phenyl; B = naphth-1-yl; and -L-G deriving from (-)-(1R, 2S)-ephedrine.

- 35 A. Formation of -NHCbz-protected 4-amino hippuric acid. N-Cbz (C₆H₅CH₂OCO-) protected 4-aminomethyl-benzoyl chloride

obtained from reaction of N- Cbz protected 4-aminomethyl-benzoic acid with oxalyl chloride was reacted with glycine.

B. Formation of oxazolone. NHCbz protected hippuric acid from step A was cyclized with dicyclohexyl carbodiimide.

5 C. Introduction of naphth-1-yl as ring system B and oxazolone ring-opening with (1R,2S)-ephedrine. This was carried out in analogy with the procedures given above for other combinations of oxazolones, aldehydes and amines. The protecting group was removed in the final step.

10

Example 9. Coupling of a ligand to EAH SEPHAROSE 4B and ECH SEPHAROSE.

EAH SEPHAROSE 4B (epoxy activated agarose that has been reacted with 1-6-diamino-hexane) or ECH SEPHAROSE (epoxy
15 activated agarose that has been reacted with 6-amino-hexane carboxylic acid) supplied preswollen in 20% ethanol (PHARMACIA BIOTECH AB, Uppsala, Sweden). The ethanol solution was decanted and the gel washed with water on a glass filter. The
gel is stepwise washed over into THF. The ligand (100-150 μ mol)
20 and dicyclohexyl carbodiimide (200 μ mol) is dissolved in THF and is then mixed with 10ml of the gel (100 μ mol amino groups). The suspension is rotated over night (18h) at room temperature. The gel is washed with 300ml THF, 300ml acetone, 300ml water, 300ml isopropanol, 300ml acetonitrile and finally
25 300ml water. Remaining groups are blocked with 1.7M acetic acid and 1M dicyclohexyl carbodiimide (DCC) in dioxan. The gel is washed with 150ml 40°C isopropanol, 300ml acetone, 300ml THF, 300ml acetonitrile, 300ml 40°C isopropanol, 300ml ethanol and 300ml water. Finally the gel is washed with alternating
30 high pH (0.1M tris-HCl + 0.5M NaCl pH 8.5) and low pH (0.1M NaAcO + 0.5M NaCl pH 4.5 with acetic acid) buffers. All together 300 ml high pH buffer and 300 ml low pH buffer were used. The results are given in Table 6.


Table 6. Coupled ligands that have affinity to HSA.

Ligand			μmol ligand	μmol DCC
A-part	B-part	-L-G from		
Thien-2-yl *	Naphth-1-yl	N-methyl-L-Phenyl-alanine	100	200
Thien-2-yl *	Naphth-1-yl	N-methyl-D-Phenyl-alanine	100	200
2-phenyl*	1-methylindol-3-yl	N-methyl-L-Phenyl-alanine	150	200
2-phenyl*	1-methylindol-3-yl	N-methyl-D-Phenyl-alanine	150	200
Thien-2-yl*	1-methylindol-3-yl	N-methyl-L-Phenyl-alanine	103	200
Thien-2-yl*	1-methylindol-3-yl	N-methyl-D-Phenyl-alanine	97	200
4-aminomethyl phenyl**	Naphth-1-yl	1R,2S-ephedrine	200	400

-L-G indicates that the amino acids indicated have been used for the ring opening of the oxazolone ring. *The final ligand bound to EAH SPHAROSE. ** The final ligand bound to ECH SEPHAROSE.

C L A I M S


1. A method for binding albumin which comprises:
contacting an aqueous liquid containing an albumin with an
albumin-binding compound (compound 1) containing the
scaffold -CO-NH-C(=C-)-CO- .
2. The method according to claim 1, wherein the compound has
the formula II:



wherein

- a. A and B are the same or different and contain a 5- or
6-membered aromatic ring directly attached to the
carbonyl or carbon-carbon-double bond, respectively, of
the scaffold;
- b. L is a linker $\text{-(CH}_2\text{)}_n\text{(X)}_{m'}\text{(CH}_2\text{)}_{n'}\text{-}$, wherein the left
and right free valences bind to the right carbonyl
group of the scaffold and to the group -G, respectively;
X is oxygen, sulphur or NH, with the H of the NH
optionally being replaced with a methyl group or a C_{2-10}
alkyl group; one or more of the hydrogen atoms in a
 CH_2 -group of the linker is optionally replaced with a
 C_{1-10} alkyl group, or a hydroxy, carboxy or amino group
or any group containing a functional group which
enables further derivatization and linking to a
carrier/conjugated partner; n and n' are integers 0-3
and m' is an integer 0 or 1, with the proviso that
 $n+n'+m'$ is 1, 2 or 3;
- c. G is a hydrophobic group;
- d. m is 0 or 1;
- e. ----- denotes that the carrier/conjugated partner, if
present, is replacing a hydrogen in the ligand;
- f. carrier/conjugated partner is a residue having a
molecular weight of more than 118 dalton and deriving
from a compound 2.

3. The method of claim 2, **wherein** $n = 0$, $m' = 1$ and $n' = 2$; X is O or NH with H being substituted with a lower C_{1-10} alkyl; one or more of the hydrogen atoms in a CH_2 -group of the linker is replaced with a C_{1-10} alkyl group, or a hydroxy, carboxy or amino group
4. The method of anyone of claims 2-3, **wherein** one or both of the aromatic rings in A and B comprise one, two or three heteroatoms providing at least one free electron pair and being selected among oxygen, nitrogen or sulphur.
5. The method of anyone of claims 2-4, **wherein** each of A and B are represented by the formula:



wherein

- A) ---- represents that R_1 and R_2 are substituting R_3 , R_4 or a hydrogen in D;
- B) the link from the aromatic ring to the scaffold $-CO-NH-C(=C)-CO-$ is through replacement of a hydrogen in D or of one of R_1 and R_2 , or one of R_3 and R_4 ;
- C) D in formula III is selected from among $-NH-CH=CH-$, $-CH=N-CH-$, $-NH-CH=N-$, $-NH-N=CH-$, $-N=N-NH-$, $-S-CH=CH-$, $-O-CH=CH-$, $-O-CH=N-$, $-S-CH=N-$, $-CH=CH-CH=CH-$, $-CH=CH-CH=N-$, $-CH=CH-N=CH-$, $-CH=CH-N=N-$, $-CH=NH-CH=N-$, $-N=CH-CH=N-$, $-N=CH-N=N-$, and $-N=CH-N=N-$;
- D) R_1 and R_2 are selected from the group consisting of:
- hydrogen (no replacement), alkyl, aryl, alkoxy, aryloxy and their thio analogues, which are optionally substituted;
 - halo;
 - nitro;
 - cyano, carboxamido and carboxy; and
 - amino, such as primary, secondary and tertiary amino and corresponding ammonium groups and acylated and alkylated forms thereof including quaternary ammonium,

E) R_3 and R_4 may be hydrogen or together form a bivalent structure selected from among the D structures given above and in addition among

5 $-\text{CH}_2-\text{S}-\text{CH}_2-$, $-\text{CH}_2-\text{O}-\text{CH}_2-$, $-\text{S}-\text{CH}_2-\text{CH}_2-$, $-\text{O}-\text{CH}_2-\text{CH}_2-$,
 $-\text{O}-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}_2-\text{O}-\text{CH}=\text{CH}-$, $-\text{S}-\text{CH}=\text{CH}-\text{CH}_2-$,
 $-\text{CH}_2-\text{S}-\text{CH}=\text{CH}-$, $-\text{S}-\text{CH}=\text{CH}-\text{NH}-$, $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$,
 $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$, and
 $-\text{CH}_2-\text{CH}_2-\text{CH}=\text{CH}-$.

10 7. The method of anyone of claims 2-5, **wherein** one or both of the aromatic rings are selected from the group consisting of phenyls, 1- and 2-naphthyls, 1- and 2-thienyls, 2- and 3- and 4-pyridyls, 2- and 3- and 4-quinolyls, 1- and 3- and 4-isoquinolyls, 2- and 3-indolyls, 2- and 3-furanyls, and

15 1-, 2- and 3-pyrrolyls.

8. The method of anyone of claims 2-6, wherein G is an aryl group or an aryl group that is substituted with hydroxy and/or C_{1-10} alkyl in the ortho, meta or para position

20 ~~relative to the ring position binding to L.~~

8. The method of anyone of claims 2-7, wherein $m = 1$ and the conjugated partner is selected from polymeric carriers or analytically detectable carriers.

25

9. The method of anyone of claims 2-8, **wherein** the conjugated partner is linked to the ligand at either the A-, B-, or L-parts.

30 10. The method of anyone of claims 2-8, **wherein** the conjugated partner is attached at either the A- or the B-part and the conjugated partner provides an sp^3 -hybridized atom within two atoms distance from the aromatic ring in the A-part or B-part to which attachment occurs.

35 11. The method of claim 10, **wherein** the conjugated partner provides the group $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2\text{NH}-$, $-\text{NHCH}_2-$, $-\text{CH}_2\text{O}-$, or $-\text{OCH}_2-$ next to the aromatic ring.

12. The method of anyone of claims 2-8, **wherein** the conjugated partner is linked to L at a -CONH- or -COO- group substituting a hydrogen in L.
- 5 13. The method of anyone of claims 2-12, **wherein** $n = 0$, $n' = 2$, $m' = 1$, $X = O$ or NH , with H in the NH optionally being substituted with a lower C_{1-10} alkyl.
- 10 14. The method of anyone of claims 2-12, **wherein** the conjugated partner is a support matrix for affinity adsorption.
15. A conjugate having the formula II:
- 15 (A-CO-NH-C(=CH-B)-CO-L-G)----- conjugated partner) $_m$
- wherein** A, B, and G and ---- are as defined in anyone of claims 2-14; $m = 1$, wherein the conjugated partner is linked to the ligand either at the A-, B-, or L-part.
- 20 16. The conjugate of claim 15, **wherein** the conjugated partner is attached to the ligand at the aromatic ring of either the A- or the B-part and the conjugated partner provides an sp^3 -hybridized carbon atom within a distance
- 25 of two atoms from the aromatic ring of the A- or the B-part to which the attachment occurs.
- 30 17. The conjugate of claim 16, **wherein** the conjugated partner provides -CH₂-CH₂-, -CH₂NH-, -NHCH₂-, -CH₂O-, or -OCH₂- next to the aromatic ring.
- 35 18. The conjugate of claim 15, **wherein** the conjugated partner is linked to L at a -CONH- or -COO- group substituting a hydrogen in L.
19. The conjugate of claim 15, **wherein** $n = 0$, $n' = 2$, $m' = 1$, $X = O$ or NH , with H in the NH optionally being replaced by a lower C_{1-10} alkyl.

20. The conjugate of anyone of claims 15-19, **wherein** the conjugated partner is a support matrix for affinity adsorption.
21. The method of anyone of claims 2-14, **wherein** a hydrogen
5 in NH of L is replaced with a methyl group or a C₂₋₁₀ alkyl group.
22. The method of anyone of claims 5-14, **wherein** said groups
10 R₁ and R₂ are substituted with at least one halo group
23. The method of anyone of claims 5-14, **wherein** said R₁ and
R₂ are C₁₋₁₀ alkyl or C₅₋₁₅ aryl group, optionally
substituted with one or more lower alkyl or halo groups,
e.g., -CF₃,
15 -CH₃.
24. The method of anyone of claims 5-14, **wherein** R₁ and R₂
are phenyl.
- ~~20 25. The method of anyone of claims 5-14, **wherein** a hydrogen~~
in NH of L is replaced with a methyl group or a C₂₋₁₀
alkyl group.
26. The method of anyone of claims 5-14, **wherein** said
25 support matrix is a chromatographic support matrix.
27. The conjugate of anyone of claims 5-14, **wherein** said
support matrix is a chromatographic support matrix.
- 30 28. An albumin-binding compound that has been obtained by
changing a part of the structure of an albumin binder
defined in any of the preceding claims.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02468

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 1/14, C07K 1/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, REG, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9602573 A1 (GENE PHARMING EUROPE BV), 1 February 1996 (01.02.96) --	1-28
A	WO 9622529 A1 (ARQULE, INC.), 25 July 1996 (25.07.96) --	1-28
A	US 5663306 A (LOIS ALDWIN ET AL), 2 Sept 1997 (02.09.97) -- -----	1-28

☐

Further documents are listed in the continuation of Box C.

☒

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 April 1999

Date of mailing of the international search report

03 -05- 1999

Name and mailing address of the ISA,

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

07/04/99

International application No.

PCT/SE 98/02468

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9602573 A1	01/02/96	AU 2989495 A CA 2195202 A EP 0773961 A GB 9414651 D JP 10504289 T	16/02/96 01/02/96 21/05/97 00/00/00 28/04/98
WO 9622529 A1	25/07/96	AU 4705996 A CA 2210949 A CZ 9702322 A EP 0804726 A HU 9802293 A IL 116838 D NO 973335 A NZ 301594 A PL 327437 A US 5712171 A US 5736412 A	07/08/96 25/07/96 17/06/98 05/11/97 01/02/99 00/00/00 21/08/97 28/01/99 07/12/98 27/01/98 07/04/98
US 5663306 A	02/09/97	NONE	

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)